National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer
Open Access
- 18 October 2026
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 220 (1) , 6
Abstract
Purpose: De-escalation has become standard across breast cancer management. Many early-stage HR+/HER2-negative breast cancers are eligible for both SLNB omission and accelerated partial breast irradiation (APBI). However, the oncologic safety of dual de-escalation has not been evaluated except in patients ≥ 70 years. We sought to characterize national practice patterns and factors associated with adoption of this dual de-escalation approach. Methods: Women aged 50–69 years with clinical T1–T2N0 breast cancer who underwent upfront breast-conserving surgery between (2012 − 2022) were identified from the National Cancer Database. Patients were categorized by axillary surgery and by adjuvant radiation modality (WBI, APBI, or none). We assessed trends and factors associated with de-escalation. Results: 316,324 patients met inclusion criteria, of whom 98% underwent SLNB. Among patients who underwent SLNB, 83% received WBI, 11% received APBI, and 6% received no radiation. In contrast, among patients in whom SLNB was omitted, 63% received WBI, 8% received APBI, and 30% received no radiation. SLNB omission remained low throughout the study period at < 3%, while APBI use increased from 8% to 16.5%. Dual de-escalation was rarely performed throughout the study period remaining < 0.30%. Shared predictors of de-escalation included cT1 tumors, ductal histology, low grade, and treatment at academic/research programs. Conclusion: These findings highlight the need for prospective studies to define the safety, outcomes, and patient selection criteria for combined de-escalation strategies. Until these data are available, patient-centered discussions are essential to determine the most appropriate strategy for patients with low-risk disease.Keywords
Funding Information
- Marlyn Fein Chapter of Fox Chase Cancer Center Board of Associates
This publication has 23 references indexed in Scilit:
- Axillary Surgery in Breast Cancer — Primary Results of the INSEMA TrialNew England Journal of Medicine, 2025
- Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice GuidelinePractical Radiation Oncology, 2023
- Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph NodesJAMA Oncology, 2023
- De-escalation in breast cancer surgerynpj Breast Cancer, 2022
- Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature reviewStrahlentherapie und Onkologie, 2021
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trialThe Lancet, 2019
- Using the National Cancer Database for Outcomes ResearchJAMA Oncology, 2017
- Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus StatementPractical Radiation Oncology, 2017
- Not Performing a Sentinel Node Biopsy for Older Patients With Early-Stage Invasive Breast CancerJAMA Surgery, 2015
- Socioeconomic Disparities in Breast Cancer Treatment Among Older WomenJournal of Women's Health, 2014